Literature DB >> 22205621

New developments in small molecular compounds for anti-hepatitis C virus (HCV) therapy.

Jing Tong1, You-wei Wang, Yuan-an Lu.   

Abstract

Infection with hepatitis C virus (HCV) affects approximately 170 million people worldwide. However, no vaccine or immunoglobulin is currently available for the prevention of HCV infection. The standard of care (SOC) involving pegylated interferon-α (PEG-IFN α) plus ribavirin (RBV) for 48 weeks results in a sustained virologic response in less than 50% of patients with chronic hepatitis C genotype 1, the most prevalent type of HCV in North America and Europe. Recently, reliable in vitro culture systems have been developed for accelerating antiviral therapy research, and many new specifically targeted antiviral therapies for hepatitis C (STAT-C) and treatment strategies are being evaluated in clinical trials. These new antiviral agents are expected to improve present treatment significantly and may potentially shorten treatment duration. The aim of this review is to summarize the current developments in new anti-HCV drugs.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22205621      PMCID： PMC3251753          DOI： 10.1631/jzus.B1100120

Source DB:  PubMed          Journal:  J Zhejiang Univ Sci B        ISSN： 1673-1581            Impact factor:   3.066


  88 in total

Review 1.  Prospects for a vaccine against the hepatitis C virus.

Authors:  Michael Houghton; Sergio Abrignani
Journal:  Nature       Date:  2005-08-18       Impact factor: 49.962

2.  Robust production of infectious hepatitis C virus (HCV) from stably HCV cDNA-transfected human hepatoma cells.

Authors:  Zhaohui Cai; Chen Zhang; Kyung-Soo Chang; Jieyun Jiang; Byung-Chul Ahn; Takaji Wakita; T Jake Liang; Guangxiang Luo
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

3.  SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells.

Authors:  B A Malcolm; R Liu; F Lahser; S Agrawal; B Belanger; N Butkiewicz; R Chase; F Gheyas; A Hart; D Hesk; P Ingravallo; C Jiang; R Kong; J Lu; J Pichardo; A Prongay; A Skelton; X Tong; S Venkatraman; E Xia; V Girijavallabhan; F G Njoroge
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191

Review 4.  Progress towards improving antiviral therapy for hepatitis C with hepatitis C virus polymerase inhibitors. Part I: Nucleoside analogues.

Authors:  Nathaniel A Brown
Journal:  Expert Opin Investig Drugs       Date:  2009-06       Impact factor: 6.206

Review 5.  The way forward in HCV treatment--finding the right path.

Authors:  Michael P Manns; Graham R Foster; Jürgen K Rockstroh; Stefan Zeuzem; Fabien Zoulim; Michael Houghton
Journal:  Nat Rev Drug Discov       Date:  2007-12       Impact factor: 84.694

6.  Evaluation of VCH-759 monotherapy in hepatitis C infection.

Authors:  Curtis Cooper; Eric J Lawitz; Peter Ghali; Maribel Rodriguez-Torres; Frank H Anderson; Samuel S Lee; Jean Bédard; Nathalie Chauret; Roch Thibert; Isabel Boivin; Olivier Nicolas; Louise Proulx
Journal:  J Hepatol       Date:  2009-04-23       Impact factor: 25.083

Review 7.  Antiviral therapy for chronic hepatitis C: past, present, and future.

Authors:  Norio Hayashi; Tetsuo Takehara
Journal:  J Gastroenterol       Date:  2006-01       Impact factor: 6.772

8.  Discovery of (R)-6-cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-3-((5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl)-4-hydroxy-5,6-dihydropyran-2-one (PF-00868554) as a potent and orally available hepatitis C virus polymerase inhibitor.

Authors:  Hui Li; John Tatlock; Angelica Linton; Javier Gonzalez; Tanya Jewell; Leena Patel; Sarah Ludlum; Matthew Drowns; Sadayappan V Rahavendran; Heather Skor; Robert Hunter; Stephanie T Shi; Koleen J Herlihy; Hans Parge; Michael Hickey; Xiu Yu; Fannie Chau; Jim Nonomiya; Cristina Lewis
Journal:  J Med Chem       Date:  2009-03-12       Impact factor: 8.039

9.  Antiviral therapy for hepatitis C virus: beyond the standard of care.

Authors:  Leen Delang; Lotte Coelmont; Johan Neyts
Journal:  Viruses       Date:  2010-03-29       Impact factor: 5.818

Review 10.  Genetic diversity and evolution of hepatitis C virus--15 years on.

Authors:  Peter Simmonds
Journal:  J Gen Virol       Date:  2004-11       Impact factor: 3.891
View more
  3 in total

Review 1.  Association between serum vitamin D and severity of liver fibrosis in chronic hepatitis C patients: a systematic meta-analysis.

Authors:  Yue-qiu Luo; Xiao-xing Wu; Zong-xin Ling; Yi-wen Cheng; Li Yuan; Charlie Xiang
Journal:  J Zhejiang Univ Sci B       Date:  2014-10       Impact factor: 3.066

2.  In search of drugs to alleviate suppression of the host's innate immune responses against SARS-CoV-2 using a molecular modeling approach.

Authors:  Shuvasish Choudhury; Debojyoti Moulick; Anupom Borah; Purbajyoti Saikia; Muhammed Khairujjaman Mazumder
Journal:  In Silico Pharmacol       Date:  2021-04-04

3.  Clinical Trial Risk in Hepatitis C: Endpoint Selection and Drug Action.

Authors:  Nicole A Tillie; Jayson L Parker; Jordan J Feld
Journal:  Can J Gastroenterol Hepatol       Date:  2016-03-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.